Physician profile
Donna Davis
NPI 1932155686
$2,846.27
in general payments reported to CMS, 2019-2025
22 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $491 · 2021: $476 · 2022: $440 · 2023: $306 · 2024: $371 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $579.03 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $439.85 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $317.87 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $181.82 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $177.66 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $172.47 | 2019-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $159.98 | 2019-2021 | |
| Shire North American Group INC | $140.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $129.13 | 2019-2022 | |
| Alkermes, INC. | $128.66 | 2020-2022 | |
| Adlon Therapeutics L.P. | $86.84 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $61.20 | 2021 | |
| Allergan, INC. | $55.35 | 2019-2020 | |
| Abbvie INC. | $39.73 | 2023-2025 | Vraylar |
| Dexcom, INC. | $30.88 | 2024-2025 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.65 | 2024-2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $24.78 | 2024 | Xelstrym |
| Jazz Pharmaceuticals INC. | $24.45 | 2019 | |
| Lilly USA, LLC | $19.19 | 2024 | Mounjaro, Zepbound |
| Collegium Pharmaceutical, INC. | $19.15 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $15.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.